- Home
- Our Company
- Our societal impact
- Global Health Equity
- Tuberculosis
Tuberculosis
Despite being preventable and curable, tuberculosis (TB) is among the world’s deadliest infectious diseases, killing 1.6 million people in 2021—more than HIV/AIDS and malaria combined. Underserved communities bear the largest burden, with more than 95% of TB-related deaths occurring in low- and middle-income countries, but this airborne disease knows no borders.
Expand
Collapse
Recognizing 10 years of impact enabled by our medicine for Multidrug-Resistant TB
In 2012, our medicine for pulmonary MDR-TB was granted accelerated approval by the United States Food and Drug Administration (U.S. FDA) for use as part of a combination therapy in adults when an effective treatment regimen cannot otherwise be provided. This was the first targeted TB drug with a novel mechanism of action to be approved in more than 40 years.
Expand
Collapse
By the numbers
600k+
Courses of our medicine
delivered to date
delivered to date
158
Countries accessing our medicine, including the 30 highest-burden countries
72
Countries in which our
medicine has been approved
medicine has been approved
-
To build a world without TB, we must bring this disease out of the shadows and address the biggest barriers that prevent people from seeking care. Young people can play a key role in bringing about this change, which is why it’s so important to meaningfully invest in the potential of youth as champions of change for themselves, their families, their peers and their communities.
Anna CaravaggioVice President, Global Public Health Franchises, Johnson & Johnson -
Johnson & Johnson is advancing the fight against TB by doing much beyond the pill. We are engaging with partners at the national and international levels to ensure that we work with them to build the capacity and the systems needed to ensure that treatment is accessible.
Rachana AcharyaAssociate Director, Infectious Diseases and Vaccines, Janssen India
News and updates
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations
“We want a world without tuberculosis in our lifetimes”
Healthcare providers who contracted TB on the job. A microbiologist researching new treatments. An activist ensuring attention is paid to one of the world’s greatest health threats. These young leaders share one goal: to help end TB.
Pathway to progress
2002
New compound is identified
Janssen investigates possible compound for the treatment of MDR-TB.
2004
Janssen makes breakthrough discovery
Janssen researchers create new anti-TB treatment using a new compound identified two years earlier that is able to kill off TB bacteria by blocking a specific enzyme. This research is published in Science one year later.
2012
Medicine receives accelerated FDA approval
Our MDR-TB medicine is granted accelerated approval by the U.S. FDA as the first targeted drug with a novel mechanism of action against TB in more than 40 years.
2013
Agreement signed for Russia and CIS
Our company enters a commercial licensing agreement with JSC Pharmstandard for for the registration, commercialization and manufacturing of MDR-TB medicine for Russia and several other countries in the region.
2014
Johnson & Johnson enters collaboration with Global Drug Facility
This partnership with a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF) helps to facilitate access to the company’s MDR-TB medicine.
2014
Collaboration announced to further evaluate medicine
Janssen announces collaboration with the International Union Against TB and Lung Disease (The Union) to include our MDR-TB medicine in two arms of the STREAM study, an ongoing trial to evaluate MDR-TB treatment regimens.
2015
Johnson & Johnson launches four-year Donation Program
Our company commits to donate courses of our medicine, free of charge, in up to 110 eligible countries through a donation program with USAID and Pharmastand, ultimately donating 105,000 courses from 2015-2019.
2015
MDR-TB Medicine added to WHO Essential Medicines List
MDR-TB Medicine Added to WHO Essential Medicines List
2016
Janssen wins prestigious international award
Our MDR-TB medicine receives an International Prix Galien Award, recognizing excellence in scientific innovation to improve human health.
2017
An innovation-focused research collaboration is formed in India
Johnson & Johnson announces a collaboration with India’s Institute of Microbial Technology (IMTech) that’s focused on discovering new treatments for TB.
2018
South African Government leads the way
South Africa becomes the first country to recommend a bedaquiline-containing, injection-free regimen for all eligible MDR-TB patients.
2018
Johnson & Johnson offers not-for-profit price to eligible countries
Johnson & Johnson announced that our MDR-TB medicine would be made available at a not-for-profit price to more than 130 countries procuring our medicine through the Stop TB Partnership’s Global Drug Facility.
2018
Johnson & Johnson announces 10-year TB initiative
Johnson & Johnson announces new 10-year TB initiative aimed at improving patient finding, expanding treatment access and advancing R&D at the first UN High Level Meeting on TB.
2019
Johnson & Johnson launches new R&D collaboration
Johnson & Johnson partners with the EU’s Innovative Health Initiative and eight European academic and research institutions to launch a new collaborative, RESPIRI-TB, aimed at accelerating the discovery of new TB medicines. The initiative later launches UNITE4TB in 2021.
2019
J&J commits $500 million to help end HIV and TB
J&J announces four-year commitment, focused on developing new innovations and accelerating the delivery of existing and new tools to combat both epidemics.
2019
FDA approves our MDR-TB medicine for adolescents
The U.S. FDA grants approval for the medicine as part of combination therapy for eligible patients over the age of 12 and younger than 18 with pulmonary multidrug-resistant tuberculosis (MDR-TB).
2019
WHO recommends all-oral DR-TB treatment regimens
The World Health Organization (WHO) recommends the use of all-oral regimens containing our medicine for all drug-resistant tuberculosis patients.
2019
New global collaboration to develop transformative treatments
Johnson & Jonson joins a global consortium of philanthropic, non-profit and private sector organizations to accelerate the development of novel “pan-TB” treatment regimens.
2020
FDA approves pediatric formulation of our MDR-TB medicine
Johnson & Johnson receives the first regulatory approval for the pediatric formulation of our medicine, which is later also approved by the European Commission in March 2021.
2020
J&J and partners announce efforts to scale-up access
J&J and Stop TB Partnership announce joint efforts to accelerate scale-up of WHO-recommended, all-oral treatment regimens and drive progress toward the global goal of ending TB.
2021
J&J announces initiatives to find the “missing millions”
Johnson & Johnson announces five initiatives to help find and deliver care to the “missing millions” of adults and children living with TB who have not yet been diagnosed.
2021
J&J launches Centers for Global Health Discovery
First Satellite Center for Global Health Discovery is launched at the London School of Hygiene & Tropical Medicine, aimed at accelerating new TB drug regimens.
2022
PAN-TB collaboration announces execution of a joint development agreement (JDA)
Johnson & Johnson joins with PAN-TB collaboration to announce the progression of two investigational TB combination regimens into phase 2 clinical development.
2022
J&J Announces New Youth-Focused Initiatives
Johnson & Johnson announces a series of initiatives aimed at helping empower a generation of youth to end TB in support of the Company’s efforts to help find the “missing millions.”